Open an account

Bausch Health Companies

BHC · TORONTO

$6.42+$0.10 (+1.58%)TodayMarket closed ·
Prev close $6.32

About BHC

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,300 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.

Employees
20,300
Headquarters
Laval, Quebec
Listed
Sep 20, 1994
Sector
Health Care
Industry
Pharmaceuticals
Website
bauschhealth.com

BHC key statistics

Market cap
3.35B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.83M
Volume
2.03M
Open price
$6.42
High today
$6.54
Low today
$6.36
52 Week high
$8.00
52 Week low
$4.33

Bausch Health Companies (BHC) at a glance

Bausch Health Companies (BHC) last traded at $6.42, with a market cap of 3.35B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.36 and $6.54. The current price is 0.9% above the day's low and 1.8% below its high.

Volume so far is 2.03M shares, in line with the average of 1.83M shares a day.

Over the past year Bausch Health Companies has ranged from $4.33 to $8.00, and now sits 57% of the way up that range.

Bausch Health Companies met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $1.26 per share against an estimate of $1.05.

The average analyst price target is $6.45, 0.5% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 3 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 2 analystsAvg $6.45
Low
$6.39
Now
$6.42
High
$6.64

BHC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 10.3% on average.

  1. Q3 FY24: reported $1.13 per share against an estimate of $1.07
  2. Q4 FY24: reported $1.15 per share against an estimate of $1.20
  3. Q1 FY25: reported $0.60 per share against an estimate of $0.8014
  4. Q2 FY25: reported $0.91 per share against an estimate of $0.9792
  5. Q3 FY25: reported $1.16 per share against an estimate of $1.13
  6. Q4 FY25: reported $1.10 per share against an estimate of $1.28
  7. Q1 FY26: reported $0.78 per share against an estimate of $0.6944
  8. Q2 FY26: reported $1.26 per share against an estimate of $1.05

BHC news

  • Press releasePRNewswire

    Bausch Health Canada Announces Expanded Public Reimbursement for (Pr)OKEDI® (Risperidone for Extended-Release Injectable Suspension) Across Canada for the Treatment of Schizophrenia

  • Neeraj Jain

    Why Is Bausch + Lomb Stock Falling Monday?

  • Press releasePRNewswire

    Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

  • Press releaseBusiness Wire

    Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

  • Press releasePRNewswire

    Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026

  • Press releasePRNewswire

    Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

  • Press releasePRNewswire

    (Pr)SILIQ® (brodalumab injection) Now Reimbursed Under Alberta's Public Drug Plan, Improving Access for Eligible Patients with Moderate to Severe Plaque Psoriasis

  • Press releasePRNewswire

    Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

Similar companies

Companies in the same industry as Bausch Health Companies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.